Vimarsana
Biggest News Aggregation in the World

Page 34 - Dave Fredrickson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dave Fredrickson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dave Fredrickson Today - Breaking & Trending Today

AstraZeneca's Lynparza Gets Approval In Japan To Treat Three Cancers - Vimarsana News

AstraZeneca's Lynparza Gets Approval In Japan To Treat Three Cancers

AstraZeneca's Lynparza Gets Approval In Japan To Treat Three Cancers Mon, 28th Dec 2020 08:05 (Alliance News) - AstraZeneca PLC said Monday its Lynparza cancer treatment has secured approval in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers. Astra jointly develops and commercialises the drug with US pharmaceutical company Merck & Co Inc. The pair signed a global strategic oncology collaboration to co-develop and co-commercialise Lynparza in July 2017. The concurrent approvals by the Japanese Ministry of Health, Labour & Welfare are based on positive results from...

Source: lse.co.uk
AstraZeneca's Tagrisso approved in the US for early lung cancer - Vimarsana News

AstraZeneca's Tagrisso approved in the US for early lung cancer

AstraZeneca plc (LON:AZN)’s  Tagrisso (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumour resection with curative intent.  Tagrisso is indicated for EGFRm patients whose tumours have exon 19 deletions or exon 21 L858R mutations as detected by an approved test. The approval was granted under the US Food and Drug Administration’s (FDA) Real-Time Oncology Review (RTOR) pilot program. Five other countries participated in a concurrent submissi...

TAGRISSO Approved in the US for the Adjuvant Treatment of Patients With Early-Stage EGFR-mutated Lung Cancer - Vimarsana News

TAGRISSO Approved in the US for the Adjuvant Treatment of Patients With Early-Stage EGFR-mutated Lung Cancer

TAGRISSO Approved in the US for the Adjuvant Treatment of Patients With Early-Stage EGFR-mutated Lung Cancer Approval based on unprecedented results from the ADAURA Phase III trial where TAGRISSO WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s TAGRISSO ® (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumor resection with curative intent. TAGRISSO is indicated for EGFRm patients whose tumors have exon 19 deletions or exon 21 L858R mutations as ...

ADDING MULTIMEDIA TAGRISSO Approved in the US for the Adjuvant Treatment of Patients With Early-Stage EGFR-mutated Lung Cancer - Vimarsana News

ADDING MULTIMEDIA TAGRISSO Approved in the US for the Adjuvant Treatment of Patients With Early-Stage EGFR-mutated Lung Cancer

ADDING MULTIMEDIA TAGRISSO Approved in the US for the Adjuvant Treatment of Patients With Early-Stage EGFR-mutated Lung Cancer Approval based on unprecedented results from the ADAURA Phase III trial where TAGRISSO WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s TAGRISSO ® (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumor resection with curative intent. TAGRISSO is indicated for EGFRm patients whose tumors have exon 19 deletions or exon 21 L...

Green light for AZ's Tagrisso in early-stage lung cancer - Vimarsana News

Green light for AZ's Tagrisso in early-stage lung cancer

Green light for AZ’s Tagrisso in early-stage lung cancer 21st December 2020 The US Food and Drug Administration (FDA) has approved AstraZeneca’s Tagrisso (osimertinib) for the treatment of adult patient with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). The FDA regulatory submission for Tagrisso was reviewed under the agency’s real-time oncology review (RTOR) pilot programme, which aims to make safe and effective treatments available to patients ‘as early as possible’. The approval was based on results from AZ’s ADAURA phase III t...